Selected article for: "adaptive innate and immune activation"

Author: Brain, Danielle; Plant-Hately, Alex; Heaton, Bethany; Arshad, Usman; David, Christopher; Hedrich, Christian; Owen, Andrew; Liptrott, Neill J.
Title: Drug delivery systems as Immunomodulators for therapy of infectious disease: relevance to COVID-19
  • Cord-id: nof0bv1i
  • Document date: 2021_6_25
  • ID: nof0bv1i
    Snippet: The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an unprecedented response to identify therapies that can limit uncontrolled inflammation observed in patients with moderate to severe COVID-19. The immune pathology behind COVID-19 is complex and involves the activation and interaction of multiple systems including, but not limited to, complement, inflammasomes, endothelial as well as innate and adaptive immune cells to bring about a convoluted profile of inflammation,
    Document: The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an unprecedented response to identify therapies that can limit uncontrolled inflammation observed in patients with moderate to severe COVID-19. The immune pathology behind COVID-19 is complex and involves the activation and interaction of multiple systems including, but not limited to, complement, inflammasomes, endothelial as well as innate and adaptive immune cells to bring about a convoluted profile of inflammation, coagulation and tissue damage. To date, therapeutic approaches have focussed on inhibition of coagulation, untargeted immune suppression and/or cytokine-directed blocking agents. Regardless of recently achieved improvements in individual patient outcomes and survival rates, improved and focussed approaches targeting individual systems involved is needed to further improve prognosis and wellbeing. This review summarizes the current understanding of molecular and cellular systems involved in the pathophysiology of COVID-19, and their contribution to pathogen clearance and damage to then discuss possible therapeutic options involving immunomodulatory drug delivery systems as well as summarising the complex interplay between them.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute differ: 1, 2
    • action mechanism and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • action mechanism and acute inflammation: 1, 2, 3, 4
    • action mechanism and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • action mechanism and acute phase: 1, 2, 3, 4
    • action mechanism and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lmwh weight heparin: 1
    • action mechanism and long term adherence: 1
    • action mechanism and long term effect: 1
    • action mechanism and long treatment: 1, 2, 3, 4, 5
    • action mechanism and low dosage: 1
    • action mechanism and low level production: 1
    • action mechanism and low molecular lmwh weight heparin: 1
    • action mechanism and low plasma: 1
    • action mechanism and low potency: 1, 2
    • action mechanism and low respiratory: 1
    • action mechanism and lps induce: 1
    • action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14